Furthermore, using a C5aR knock-in mouse model, the study showed that administration of anti-C5aR monoclonal antibodies eliminated C5aR-mediated activation and infiltration of myeloid cells thus preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients [98]. The gene discussed is C5AR1; the disease is acute respiratory distress syndrome.